Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant human interleukin-11 variant vs rhIL-11 for chemotherapy-induced thrombocytopenia
CTR20130758Phase 3Active
- Sponsor
- Northland Biotech
- Start
- Apr 2015
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human interleukin-11 variant in chemotherapy-induced thrombocytopenia (CIT), sponsored by Northland Biotech. Started Apr 2015; status: active.
02
Drugs
recombinant human interleukin-11 variant
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on CTR20130758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130758.